rupiya.io
⠋Loading...
0%
❯ Compiling peer comparison...
Alembic Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Alembic Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,056 Cr | ₹3,166 Cr | ₹3,105 Cr | ||||||||
| Expenses | ₹1,653 Cr | ₹2,159 Cr | ₹2,490 Cr | ||||||||
| Operating Profit | ₹403 Cr | ₹1,007 Cr | ₹615 Cr | ||||||||
| OPM % | 20.0% | 32.0% | 20.0% | ||||||||
| Other Income | ₹4 Cr | ₹7 Cr | ₹2 Cr | ||||||||
| Depreciation | ₹44 Cr | ₹72 Cr | ₹83 Cr | ||||||||
| Interest | ₹4 Cr | ₹5 Cr | ₹5 Cr | ||||||||
| Profit Before Tax | ₹359 Cr | ₹936 Cr | ₹529 Cr | ||||||||
| Tax | ₹359 Cr | ₹936 Cr | ₹529 Cr | ||||||||
| Net Profit | ₹283 Cr | ₹720 Cr | ₹403 Cr | ||||||||
| EPS (₹) | 15.0 | 38.2 | 21.4 | ||||||||
| Dividend Payout % | 23% | 9% | 19% |
Register free to see 8 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,406 Cr | ₹1,486 Cr | ₹1,595 Cr | ₹1,631 Cr | ||||||||
| Expenses | ₹1,203 Cr | ₹1,287 Cr | ₹1,387 Cr | ₹1,364 Cr | ||||||||
| Operating Profit | ₹204 Cr | ₹199 Cr | ₹208 Cr | ₹266 Cr | ||||||||
| OPM % | 14.0% | 13.0% | 13.0% | 16.0% | ||||||||
| Depreciation | ₹74 Cr | ₹66 Cr | ₹68 Cr | ₹69 Cr | ||||||||
| Interest | ₹14 Cr | ₹14 Cr | ₹16 Cr | ₹15 Cr | ||||||||
| Net Profit | ₹153 Cr | ₹121 Cr | ₹137 Cr | ₹180 Cr | ||||||||
| EPS (₹) | 7.8 | 6.1 | 7.0 | 9.2 |
Register free to see 8 more quarters.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹38 Cr | ₹38 Cr | ₹38 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹847 Cr | ₹1,560 Cr | ₹1,865 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹264 Cr | ₹114 Cr | ₹89 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹493 Cr | ₹718 Cr | ₹698 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,641 Cr | ₹2,429 Cr | ₹2,689 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹547 Cr | ₹708 Cr | ₹799 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹2 Cr | ₹87 Cr | ₹50 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹1,009 Cr | ₹1,541 Cr | ₹1,444 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,641 Cr | ₹2,429 Cr | ₹2,689 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 8 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹172 Cr | ₹-256 Cr | ₹87 Cr | — |
| Mar 2017 | ₹948 Cr | ₹-307 Cr | ₹-224 Cr | — |
| Mar 2018 | ₹329 Cr | ₹-486 Cr | ₹-129 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 8 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.